Can­cer spe­cial­ist Hi­ber­Cell snaps up an­a­lyt­ics, com­pu­ta­tion­al tools in all-stock buy­out; Prax­is re­veals new per­i­menopausal de­pres­sion da­ta

In a slight­ly un­con­ven­tion­al deal, New York-based Hi­ber­Cell is lever­ag­ing a chunk of its stock — still pri­vate­ly owned — to buy out Ge­nu­ity Sci­ence and its suite of tools for ge­nomics and mul­ti-om­ic an­a­lyt­ics, as well as an AI and ma­chine learn­ing plat­form.

The goal, ac­cord­ing to CEO Alan Rig­by, is to fur­ther Hi­ber­Cell’s un­der­stand­ing of the adap­tive stress phe­no­type and its role in can­cer pro­gres­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.